Log ind
Lars Marcher 213.jpg
Foto: Ambu/PR

Ambu CEO appointed chairman of Swedish rehab group

Top picks in English:

Sweden-based health tech and rehab group Handicare has elected Ambu’s CEO, Lars Marcher, as chairman of its board of directors. It brings another Danisn touch to the company whose majority shareholder is a fund managed by a Danish investor.


BY ELIZABETH MØNSTED JOHANSEN
Offentliggjort 22.02.17 kl. 15:15

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Novo Nordisk jumps on the discount wagon

Novo Nordisk flag-version2.jpg Top picks in English:

Novo Nordisk’s US unit has struck a deal with CVS Health for a new savings program that will give some patients up to 80 percent reduction on some of the group’s insulin products. It thus looks like times are changing in the Denmark-based insulin giant.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Biotech and CRO outfit Gubra continues explosive growth

Top picks in English:

Thanks to a successful gamble on one particular niche, Denmark’s Gubra has managed to quadruple its employee base in just a few years. The two-pronged business is set to expand significantly in the future.

“You have to remember that investment is a long-term business”

Top picks in English:

Although its asset value and net result both dipped significantly in 2016, the new CEO of Novo A/S, Kasim Kutay, is very optimistic on behalf of the company. The long-term trend looks good, he says, and the company is ready to increase investments and bridge the gap between two of its units.

Saniona gets go ahead for phase IIa trial in obesity disorder

Top picks in English:

Danish biotech Saniona is ready to initiate phase II studies of its lead candidate in a rare disease that leads to obesity and type 2 diabetes. The company aims to add additional endpoints to the study.

Danish hearing aid giants in global showdown

Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

Forsiden lige nu

Trump beder republikanere trække sundhedsreform tilbage

donaldtrump10.jpg Medicinal & Biotek:

Republikanerne kunne ikke samle stemmer nok til at få erstatning for Obamacare vedtaget.

Novo-chef: Trump forstår ikke kompleksiteten i alt, han udtaler sig om

Medicinal & Biotek:

Medicinalindustrien og Novo Nordisk specifikt er blevet udråbt som de store skurke i USA, hvor beskyldninger om grådighed nærmest er blevet hverdag. Verden er dog noget mere kompleks end det.

MW-indeks: Få pæne stigninger i en rød uge

Medicinal & Biotek:

Den den danske medicokoncern Coloplast var lokomotivet, der trak life science-toget på børspladsen i den forgangne uge, mens en anden ellers vækstforvænt aktør måtte se sin aktiekurs dykke.

Nyt land melder sig i konkurrencen om EMA

Medicinal & Biotek:

København har fået endnu en konkurrent om at overtage det Europæiske Lægemiddelagentur, når Storbritannien melder sig ud af EU. Denne gang er det et land, som argumenterer for, at det ikke har et agentur i forvejen.

Almirall indsender ansøgning for psoriasishåb

Medicinal & Biotek:

Den spanske medicinalkoncern Almirall og partneren Sun Pharma har taget det første skridt mod en europæisk godkendelse af deres biologiske lægemiddel til behandling af psoriasis.

Novo Nordisk tæt på godkendelse af nyt blødermiddel

Medicinal & Biotek:

Novo Nordisk har fået en positiv anbefaling om godkendelse af et nyt lægemiddel mod blødersygdommen hæmofili B af et ekspertpanel under de europæiske lægemiddelmyndighder. En ansøgning er også på bordet i USA.

ANNONCE
ANNONCE


ANNONCE